Skip to main content
. 2022 Mar 9;23(6):2944. doi: 10.3390/ijms23062944

Figure 2.

Figure 2

Addition of fibrinogen delays lysis. Clots contained 30% PNP or FDP, 16 µM phospholipids, 300 pM tissue plasminogen activator (tPA) ± FibCLOT®, RiaSTAP® or cryoprecipitate at 0.5–2 mg/mL. Clotting was initiated with 0.1 U/mL thrombin and 10.6 mM CaCl2 and the change in absorbance measured at 405 nm. (A–C) Raw lysis curves and (D–F) 50% lysis time show a clear increase in resistance to lysis with increasing fibrinogen concentration of RiaSTAP®, cryoprecipitate and FibCLOT®, respectively. (G) Correlation of 50% clot lysis times with fibrinogen concentration. Data shown are mean ± SEM, n = 4, * p < 0.05 and *** p < 0.001 compared with PNP.